Zacks Research Has Bullish Forecast for BMY Q4 Earnings

Key Points

• Zacks Research raised Bristol Myers Squibb’s Q4 2026 EPS estimate to $1.64 from $1.50 and projects FY2027 EPS of $6.20, signaling stronger expectations for the company’s earnings trajectory.
• Bristol Myers Squibb’s latest quarter exceeded expectations, with EPS of $2.04 versus the $1.60 consensus and revenue of $12.97 billion. The company also offers a quarterly dividend of $0.63 per share, yielding approximately 3.9%.
• Analyst sentiment remains generally positive, with a “Moderate Buy” consensus and an average price target of $66.06, though the company faces risks from a revived $6.7 billion lawsuit and uncertainty surrounding a potential AstraZeneca merger.

Bristol Myers Squibb Company (NYSE:BMY - Free Report) - Zacks Research increased their Q4 2026 earnings per share estimates for Bristol Myers Squibb in a report released on Thursday, August 13th. Zacks Research analyst Team now anticipates that the biopharmaceutical company will post earnings per share of $1.64 for the quarter, up from their prior estimate of $1.50. The consensus estimate for Bristol Myers Squibb's current full-year earnings is $6.96 per share. Zacks Research also issued estimates for Bristol Myers Squibb's Q1 2027 earnings at $1.40 EPS, Q2 2027 earnings at $1.73 EPS, Q3 2027 earnings at $1.54 EPS, Q4 2027 earnings at $1.52 EPS, FY2027 earnings at $6.20 EPS, Q1 2028 earnings at $1.45 EPS and Q2 2028 earnings at $1.35 EPS.

Several other research analysts also recently weighed in on BMY. Sanford C. Bernstein upgraded shares of Bristol Myers Squibb from a "market perform" rating to an "outperform" rating in a research note on Wednesday, August 5th. JPMorgan Chase & Co. boosted their price objective on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the stock an "overweight" rating in a report on Friday, July 31st. UBS Group downgraded Bristol Myers Squibb from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 5th. Roth Capital began coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They issued a "buy" rating and a $75.00 price target on the stock. Finally, Wells Fargo & Company set a $65.00 price objective on Bristol Myers Squibb and gave the company an "equal weight" rating in a research note on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Bristol Myers Squibb presently has an average rating of "Moderate Buy" and an average target price of $66.06.

Bristol Myers Squibb Trading Up 1.6%

BMY opened at $64.69 on Friday. The firm has a market capitalization of $132.15 billion, a P/E ratio of 14.25, a P/E/G ratio of 0.17 and a beta of 0.22. The firm's 50 day moving average is $59.43 and its 200-day moving average is $58.93. Bristol Myers Squibb has a 52-week low of $42.52 and a 52-week high of $68.10. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company's revenue was up 5.7% on a year-over-year basis. During the same period last year, the business posted $1.46 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS.

Bristol Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 3rd. Stockholders of record on Thursday, July 2nd were issued a dividend of $0.63 per share. The ex-dividend date of this dividend was Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 3.9%. Bristol Myers Squibb's payout ratio is 55.51%.

Hedge Funds Weigh In On Bristol Myers Squibb

Several hedge funds and other institutional investors have recently made changes to their positions in BMY. Norges Bank acquired a new position in shares of Bristol Myers Squibb during the fourth quarter valued at $1,947,272,000. AQR Capital Management LLC raised its holdings in Bristol Myers Squibb by 172.6% during the fourth quarter. AQR Capital Management LLC now owns 25,796,905 shares of the biopharmaceutical company's stock worth $1,391,485,000 after purchasing an additional 16,332,924 shares in the last quarter. BlackRock Inc. boosted its stake in Bristol Myers Squibb by 5.1% during the 2nd quarter. BlackRock Inc. now owns 180,384,994 shares of the biopharmaceutical company's stock valued at $10,393,783,000 after purchasing an additional 8,702,106 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Bristol Myers Squibb by 47.0% in the fourth quarter. Bank of New York Mellon Corp now owns 24,495,875 shares of the biopharmaceutical company's stock valued at $1,321,308,000 after buying an additional 7,837,485 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Bristol Myers Squibb by 13.1% during the fourth quarter. Geode Capital Management LLC now owns 52,638,346 shares of the biopharmaceutical company's stock worth $2,837,026,000 after acquiring an additional 6,084,046 shares during the period. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol Myers Squibb News Roundup

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA approval strengthens the growth pipeline. The FDA granted accelerated approval to ZENBEXUS, Bristol Myers Squibb’s first CELMoD therapy, in combination with Darzalex Faspro and dexamethasone for certain multiple myeloma patients as early as first relapse. The approval expands the company’s blood-cancer portfolio and could support future revenue growth. US FDA approves Bristol Myers blood cancer treatment
• Positive Sentiment: Zacks Research raised most forward EPS forecasts. The firm increased estimates for fourth-quarter 2026 EPS to $1.64 from $1.50 and FY2027 EPS to $6.20 from $5.93. It also lifted estimates for the first and second quarters of 2027 and the first and second quarters of 2028, suggesting improved expectations for Bristol Myers Squibb’s earnings trajectory. Bristol Myers Squibb analyst estimates
• Neutral Sentiment: Pipeline investment continues. Bristol Myers Squibb launched a Phase 1 study of golcadomide in a renal indication, while its broader growth portfolio reportedly accounts for 56% of revenue. These initiatives may help offset eventual generic pressure on legacy medicines, but clinical and commercial outcomes remain uncertain. Bristol Myers Squibb expands kidney pipeline
• Negative Sentiment: A $6.7 billion Celgene-related lawsuit was revived. An appeals court ruled that UMB Bank could represent former Celgene shareholders, allowing claims that Bristol Myers Squibb delayed approvals for drugs including Breyanzi to proceed. The case introduces potentially significant financial and legal exposure. Lawsuit against Bristol Myers over delayed cancer drug is revived
• Negative Sentiment: A potential AstraZeneca-Bristol Myers merger remains controversial. Reports of a possible $400 billion transaction previously pressured investor sentiment because of the deal’s scale, execution risks, financing requirements and strategic uncertainty. AstraZeneca-Bristol Myers merger analysis

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source